Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)[NCT00009646] | Phase 3 | 1,202 participants (Actual) | Interventional | 1993-11-30 | Completed |
| Lactoferrin Infant Feeding Trial - LIFT_Canada[NCT03367013] | Phase 3 | 453 participants (Actual) | Interventional | 2018-02-16 | Active, not recruiting |
| Enteral Supplementation With High-dose Docosahexaenoic Acid on the Risk for Bronchopulmonary Dysplasia in Very Preterm Infants: A Collaborative Study Protocol for an Individual Participant Data Meta-analysis[NCT05915806] | | 1,801 participants (Actual) | Interventional | 2023-07-30 | Active, not recruiting |
| Clinical Research on the Predictive Effect of Neonatal Morbidities on the Poor Outcomes to Very Low Birth-weight and Extremely Low Birth-weight Infants[NCT03104946] | | 834 participants (Actual) | Observational | 2013-09-01 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
| Article | Year |
|---|
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.JAMA, 2003, Mar-05, Volume: 289, Issue:9
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
School-age outcomes of very low birth weight infants in the indomethacin intraventricular hemorrhage prevention trial.Pediatrics, 2003, Volume: 111, Issue:4 Pt 1
Topics: Cerebral Hemorrhage; Cerebral Palsy; Cerebral Ventricles; Child; Cohort Studies; Developmental Disab | 2003 |